In recent months, the UK market has faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China and concerns over global economic recovery. Amidst these conditions, investors may find opportunities in stocks that are perceived to be trading below their fair value estimates, offering potential for growth as market dynamics evolve.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Yü Group (AIM:YU.) | £18.25 | £34.47 | 47% |
| Victorian Plumbing Group (AIM:VIC) | £0.75 | £1.38 | 45.7% |
| St. James's Place (LSE:STJ) | £10.64 | £20.70 | 48.6% |
| Polar Capital Holdings (AIM:POLR) | £7.91 | £14.32 | 44.8% |
| Playtech (LSE:PTEC) | £3.898 | £7.35 | 47% |
| Morgan Advanced Materials (LSE:MGAM) | £2.175 | £3.99 | 45.5% |
| Eurocell (LSE:ECEL) | £1.19 | £2.23 | 46.6% |
| Entain (LSE:ENT) | £5.606 | £10.63 | 47.2% |
| Bridgepoint Group (LSE:BPT) | £3.108 | £5.91 | 47.5% |
| Accsys Technologies (AIM:AXS) | £0.746 | £1.47 | 49.1% |
Underneath we present a selection of stocks filtered out by our screen.
Overview: AdvancedAdvT Limited provides software solutions and platforms across Europe, the United Kingdom, North America, and internationally with a market cap of £224.42 million.
Operations: The company generates £53.40 million in revenue from its Internet Software & Services segment.
Estimated Discount To Fair Value: 20%
AdvancedAdvT Limited is trading at £1.7, below its estimated future cash flow value of £2.13, indicating it might be undervalued based on cash flows by over 20%. Despite a drop in net income to £4.61 million for the year ended February 2026, earnings are expected to grow significantly at 32% annually, outpacing the UK market's growth rate of 11.5%. However, profit margins have decreased from 25.1% to 8.6%, and large one-off items affect financial results.
Overview: Advanced Medical Solutions Group plc develops, manufactures, and distributes products for the surgical, woundcare, and wound-closure markets internationally with a market cap of £608.03 million.
Operations: The company generates revenue from its surgical segment, which accounts for £183.45 million, and its woundcare segment, contributing £45.49 million.
Estimated Discount To Fair Value: 44.2%
Advanced Medical Solutions Group, trading at £2.81, is significantly undervalued based on its discounted cash flow value of £5.03. Despite recent volatility and a low forecasted return on equity of 13.8%, the company's earnings are expected to grow substantially at 39.8% annually, surpassing UK market growth rates. Recent corporate guidance indicates revenue growth to approximately £115.2 million for H1 2026 amidst strategic European sales expansion challenges and acquisition interest from H.B. Fuller Company valued at around £715 million enterprise value.
Overview: Kainos Group plc provides digital technology services across the United Kingdom, Ireland, the Americas, Central Europe, and internationally with a market cap of £1.08 billion.
Operations: The company generates its revenue from three main segments: Digital Services (£241.74 million), Workday Products (£81.75 million), and Workday Services (£107.61 million).
Estimated Discount To Fair Value: 32.4%
Kainos Group is undervalued, trading at £9.3 against a future cash flow value of £13.75. Despite significant insider selling recently, the company shows strong fundamentals with earnings growing 19.5% last year and forecasted revenue growth of 9.6% annually, outpacing the UK market average. While dividends are unstable, a high return on equity forecast of 40.5% suggests robust profitability potential moving forward amidst an expected stock price rise by analysts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com